CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
18F-Fluoromisonidazole +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02695628
NCT02695628Phase 2Completed
CompareCT.gov

Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT

Stanford University·interventional·Posted Mar 1, 2016·Updated Jan 31, 2024

In Brief

A Phase 2 clinical trial evaluating 18F-Fluoromisonidazole, Arterial Embolization, and 2 other interventions for Adult Liver Carcinoma and Liver Cirrhosis. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This clinical trial studies how well 18F-fluoromisonidazole (\[18F\]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. \[18F\]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by \[18F\]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Liver Carcinoma, Liver Cirrhosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 1, 2016
Enrollment StartSep 13, 2016
Primary CompletionApr 30, 2018
Study CompletionOct 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.3 years ago

Interventions

18F-Fluoromisonidazoledrug

Undergo \[18F\] FMISO PET/CT

Arterial Embolizationprocedure

Undergo transcatheter arterial embolization

Computed Tomographyother

Undergo \[18F\] FMISO PET/CT

Positron Emission Tomographyother

Undergo \[18F\] FMISO PET/CT